Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors
about
Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an exampleRetention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry.Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys.Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugsEconomic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.When is switching warranted among biologic therapies in rheumatoid arthritis?Anti-TNF in rheumatoid arthritis: an overview.Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry.Repository corticotropin injection as adjunctive therapy in patients with rheumatoid arthritis who have failed previous therapies with at least three different modes of actionDiscontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry.Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients.Transcriptional Profiling of Synovial Macrophages using Minimally Invasive Ultrasound-Guided Synovial Biopsies in Rheumatoid Arthritis.Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors.No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.Paeoniflorin Antagonizes TNF-α-Induced L929 Fibroblastoma Cells Apoptosis by Inhibiting NF-κBp65 Activation.Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice
P2860
Q26766368-0F79037E-BCE0-4C8F-9D6A-7CDFDE7A9A7CQ30991911-806DE718-6688-4D0D-81AB-A4E2D2764021Q36579912-DF3D7FF7-FC7C-46CE-8B17-037274FEC527Q37085663-F52325E4-3FD7-4AF7-A12B-EE5E4D7B6DA8Q37453027-1A541312-7CDF-47AA-AC17-A3583E8CEEF3Q37873493-A117AE14-859B-4E94-B11C-D4A907F702F0Q38027571-4BCE758F-00D1-4B1B-9E97-F915FBDC1FC6Q38344282-A879C421-1AF0-4C62-BFC8-E3351B28A378Q38540353-D3540B3E-2A23-4651-8767-8E7C7BF641C3Q38921982-3E34B94B-04D1-4284-BB2A-1F244F89B1F1Q41144274-529359AB-027F-4F8C-8061-EDAFEC25F328Q46894147-838D5147-7D06-4FA5-810F-CAF2F76CEA24Q47693399-2BE0B608-9605-457A-BD9B-8F563C761A8BQ49901596-1F12B5CE-41C6-49F0-9625-930B3AB8A592Q50034711-F1264A63-E6EC-4CDD-A5B9-1A27626AA942Q50224633-30A55C1D-D6D2-496B-958A-71C456F010DAQ53169655-C9FD476D-59E8-4963-A9B3-5F4D601CC21BQ55353655-76AC71FB-CCEE-45B6-B404-A9C29CFA8E4DQ57483996-51422B71-4E52-4BA3-967F-0D08AA96AB53
P2860
Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Evaluating the efficacy of seq ...... r necrosis factor-α inhibitors
@ast
Evaluating the efficacy of seq ...... r necrosis factor-α inhibitors
@en
type
label
Evaluating the efficacy of seq ...... r necrosis factor-α inhibitors
@ast
Evaluating the efficacy of seq ...... r necrosis factor-α inhibitors
@en
prefLabel
Evaluating the efficacy of seq ...... r necrosis factor-α inhibitors
@ast
Evaluating the efficacy of seq ...... r necrosis factor-α inhibitors
@en
P2093
P2860
P356
P1476
Evaluating the efficacy of seq ...... r necrosis factor-α inhibitors
@en
P2093
Gene V Wallenstein
John Bradley
Mark Kosinski
Regina Rendas-Baum
Samuel H Zwillich
Tamas Koncz
P2860
P2888
P356
10.1186/AR3249
P577
2011-02-16T00:00:00Z
P5875
P6179
1053673056